Balyasny Asset Management
ABOS icon

Balyasny Asset Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Balyasny Asset Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.7K Buy
+11,872
New +$29.3K ﹤0.01% 2920
2024
Q2 		– Sell
-63,949
Closed -$259K – 2506
2024
Q1 		$259K Buy
63,949
+43,371
+211% +$163K ﹤0.01% 2314
2023
Q4 		$79K Buy
+20,578
New +$61.1K ﹤0.01% 2395
2023
Q3 		– Sell
-30,222
Closed -$145K – 2200
2023
Q2 		$145K Buy
+30,222
New +$145K ﹤0.01% 2097

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Balyasny Asset Management's ABOS Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Acumen Pharmaceuticals (ABOS) in Q2 2026: 11,872 shares worth $31.7K. The stake represents ﹤0.01% of the portfolio and ranks #2920 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in ABOS as recently as Q1 2024.

Balyasny Asset Management first reported a position in ABOS in Q2 2023 and has held it in 4 quarters since. The position peaked at $259K in Q1 2024. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Balyasny Asset Management held 11,872 shares of Acumen Pharmaceuticals worth $31.7K as of Q2 2026.
  • Acumen Pharmaceuticals was a new Balyasny Asset Management position in Q2 2026.
  • Acumen Pharmaceuticals made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2920 holding.
  • Balyasny Asset Management first reported a position in Acumen Pharmaceuticals in Q2 2023 and has held it in 4 quarters since.
  • Balyasny Asset Management's Acumen Pharmaceuticals position peaked at $259K in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.